Briefing
Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy
Enrollment was stopped early because of a low ctDNA-positivity rate (8% of 1,901 tested; 5.2% on the first test) and a high rate of radiographic recurrence already present at first ctDNA positivity (72/147, 49%). Among the 40 randomized patients, median DFS was 11.4 months with niraparib vs 5.4 months with placebo (HR 0.64, 95% CI 0.30-1.39), a comparison the sample size cannot support as a conclusive efficacy result. No new safety signals for niraparib were reported.
- Design: oral
- n: 2,746 prescreened; 1,901 with at least one ctDNA result; 147 (8%) ctDNA-positive; 40 randomized (18 niraparib, 22 placebo) before early termination
- Assay: Signatera (personalized tumor-informed, whole-exome-based)